Ensysce Biosciences (ENSC) EPS (Basic) Growth (3y) (2021 - 2025)
Ensysce Biosciences (ENSC) EPS (Basic) Growth (3y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.31% |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 88.82% |
| Jun 30, 2025 | 90.24% |
| Mar 31, 2025 | 81.52% |
| Dec 31, 2024 | 86.18% |
| Sep 30, 2024 | 26.00% |
| Jun 30, 2024 | 74.83% |
| Mar 31, 2024 | 74.99% |
| Dec 31, 2023 | -29.90% |
| Sep 30, 2023 | -26.75% |
| Jun 30, 2023 | -1.03% |
| Mar 31, 2023 | -27.59% |
| Dec 31, 2022 | 34.38% |
| Sep 30, 2022 | -73.22% |
| Jun 30, 2022 | -75.42% |
| Mar 31, 2022 | -35.28% |
| Dec 31, 2021 | -86.15% |
| Sep 30, 2021 | -110.78% |
| Jun 30, 2021 | -41.63% |
| Mar 31, 2021 | -60.68% |